Hans-Georg Lerchen

Dr. Hans-Georg Lerchen

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
PHPaul Hoppenz
Paul Hoppenz
SESylvia Els-Heindl
Sylvia Els-Heindl
MKMartin Kellert
Martin Kellert
RKRobert Kuhnert
Robert Kuhnert
SSStefan Saretz
Stefan Saretz
ABAnnette Beck-Sickinger
Annette Beck-Sickinger

1 May 2017 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JWJörg Willuda
Jörg Willuda
LLLars Linden
Lars Linden
HLHans-Georg Lerchen
Hans-Georg Lerchen
CKCharlotte Kopitz
Charlotte Kopitz
BSBeatrix M Stelte-Ludwig
Beatrix M Stelte-Ludwig
BKBertolt Kreft
Bertolt Kreft
C4.4A (LYPD3) has been identified as a cancer- and metastasis-associated internalizing cell surface protein that is expressed in non–small cell lung cancer (NSCLC), with particularly high prevalence in the squamous cell carcinoma (SCC) subtype. With the exception of skin keratinocytes and esophageal endothelial cells, C4.4A expression is scarce in normal tissues, presenting an opportunity to selectively treat cancers with a C4.4A-directed antibody–drug conjugate (ADC). We have generated BAY 1129980 (C4.4A-ADC), an ADC consisting of a fully human C4.4A-targeting mAb conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. In vitro, C4.4A-ADC demonstrated potent antiproliferative efficacy in cell lines endogenously expressing C4.4A and inhibited proliferation of C4.4A-transfected A549 lung cancer cells showing selectivity compared with a nontargeted control ADC. In vivo, C4.4A-ADC was efficacious in human NSCLC cell line (NCI-H292 and NCI-H322) and patient-derived xenograft (PDX) models (Lu7064, Lu7126, Lu7433, and Lu7466). C4.4A expression level correlated with in vivo efficacy, the most responsive being the models with C4.4A expression in over 50% of the cells. In the NCI-H292 NSCLC model, C4.4A-ADC demonstrated equal or superior efficacy compared to cisplatin, paclitaxel, and vinorelbine. Furthermore, an additive antitumor efficacy in combination with cisplatin was observed. Finally, a repeated dosing with C4.4A-ADC was well tolerated without changing the sensitivity to the treatment. Taken together, C4.4A-ADC is a promising therapeutic candidate for the treatment of NSCLC and other cancers expressing C4.4A. A phase I study (NCT02134197) with the C4.4A-ADC BAY 1129980 is currently ongoing. Mol Cancer Ther; 16(5); 893–904. ©2017 AACR.

15 October 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
HLHans-Georg Lerchen
Hans-Georg Lerchen
SWSven Wittrock
Sven Wittrock
BSBeatrix Stelte‐Ludwig
Beatrix Stelte‐Ludwig
ASAnette Sommer
Anette Sommer
SBSandra Berndt
Sandra Berndt
CTCarsten Terjung
Carsten Terjung

19 November 2018 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
ADAndré Raposo Moreira Dias
André Raposo Moreira Dias
APArianna Pina
Arianna Pina
ADAmelia Dean
Amelia Dean
HLHans-Georg Lerchen
Hans-Georg Lerchen
MCMichele Caruso
Michele Caruso
CGCesare Gennari
Cesare Gennari
This work takes advantage of one of the hallmarks of cancer, that is, the presence of tumor infiltrating cells of the immune system and leukocyte‐secreted enzymes, to promote the activation of an anticancer drug at the tumor site. The peptidomimetic integrin ligand cyclo(DKP‐RGD) was found to accumulate on the surface of αvβ3 integrin‐expressing human renal cell carcinoma 786‐O cells. The ligand was conjugated to the anticancer drug paclitaxel through a Asn‐Pro‐Val (NPV) tripeptide linker, which is a substrate of neutrophil‐secreted elastase. In vitro linker cleavage assays and cell antiproliferative experiments demonstrate the efficacy of this tumor‐targeting conjugate, opening the way to potential therapeutic applications.

13 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HLHans-Georg Lerchen
Hans-Georg Lerchen
BSBeatrix M Stelte-Ludwig
Beatrix M Stelte-Ludwig
CKCharlotte Kopitz
Charlotte Kopitz
MHMelanie Heroult
Melanie Heroult
DZDmitry Zubov
Dmitry Zubov
AHAhmed Hamdy
Ahmed Hamdy
To improve tumor selectivity of cytotoxic agents, we designed VIP236, a small molecule–drug conjugate consisting of an αVβ3 integrin binder linked to a modified camptothecin payload (VIP126), which is released by the enzyme neutrophil elastase (NE) in the tumor microenvironment (TME). The tumor targeting and pharmacokinetics of VIP236 were studied in tumor-bearing mice by in vivo near-infrared imaging and by analyzing tumor and plasma samples. The efficacy of VIP236 was investigated in a panel of cancer cell lines in vitro, and in MX-1, NCI-H69, and SW480 murine xenograft models. Imaging studies with the αVβ3 binder demonstrated efficient tumor targeting. Administration of VIP126 via VIP236 resulted in a 10-fold improvement in the tumor/plasma ratio of VIP126 compared with VIP126 administered alone. Unlike SN38, VIP126 is not a substrate of P-gp and BCRP drug transporters. VIP236 presented strong cytotoxic activity in the presence of NE. VIP236 treatment resulted in tumor regressions and very good tolerability in all in vivo models tested. VIP236 represents a novel approach for delivering a potent cytotoxic agent by utilizing αVβ3 as a targeting moiety and NE in the TME to release the VIP126 payload—designed for high permeability and low efflux—directly into the tumor stroma.

15 July 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
HLHans-Georg Lerchen
Hans-Georg Lerchen
BSBeatrix Stelte-Ludwig
Beatrix Stelte-Ludwig
ASAnette Sommer
Anette Sommer
SBSandra Berndt
Sandra Berndt
ARAnne-Sophie Rebstock
Anne-Sophie Rebstock
HJHannah Jörißen
Hannah Jörißen